More unhealthy news for the drug biz

Article

These aren't happy times for the pharmaceutical industry. Day by day, bad news accumulates, and even the Pharmaceutical Research and Manufacturers Association (PhRMA), the industry's trade organization, acknowledges that something has to give:

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!
Recent Videos
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Lori Handy, MD on importance of vaccine catch-up before the school year | Image credit: CHOP
Richard Wong, DO, explains challenges children with asthma face in school
Infectious Insights | Image Credit: Contemporary Pediatrics
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Related Content
FDA grants fast track to rezpegaldesleukin for severe alopecia areata in ages 12 and up | Image credit: Contemporary Pediatrics

FDA grants fast track to rezpegaldesleukin for severe alopecia areata in ages 12 and up

Joshua Fitch, Senior Editor
July 29th 2025
Article

Nektar Therapeutics remains on track to announce topline phase 2 data in December.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
FDA approves pegcetacoplan as first treatment for C3 glomerulopathy or IC-MPGN | Image credit: Contemporary Pediatrics

FDA approves pegcetacoplan as first treatment for C3 glomerulopathy or IC-MPGN

Joshua Fitch, Senior Editor
July 29th 2025
Article

Pegcetacoplan (Empaveli: Apellis PHarmaceuticals) is indicated for patients aged 12 years and older to reduce proteinuria.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
FDA approves sepiapterin to treat phenylketonuria in adult, pediatric patients

FDA approves sepiapterin to treat phenylketonuria in adult, pediatric patients

Joshua Fitch, Senior Editor
July 29th 2025
Article

“Without treatment, individuals with PKU would have very high blood Phe levels... so that results in neurocognitive deficits and mood disorders," Suzanne Hollander, MS, RD, LDN.

FDA approves avatrombopag for pediatric immune thrombocytopenia, including new sprinkle formulation | Image credit: Contemporary Pediatrics

FDA approves avatrombopag for pediatric immune thrombocytopenia, including new sprinkle formulation

Morgan Ebert, Managing Editor
July 28th 2025
Article

The FDA has approved avatrombopag and new sprinkle formulation for children ≥1 year with chronic ITP, offering an oral, food-flexible treatment option.

© 2025 MJH Life Sciences

All rights reserved.